Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Wenyu Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5025-5376; OpenAlex author ID A5100665050. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 12

  1. ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. First author DOI 10.1080/14796694.2025.2522061↗
  2. Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. Co-author DOI 10.1080/1750743x.2025.2533112↗
  3. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. First author DOI 10.1016/j.radonc.2023.109941↗
  4. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s13014-024-02493-8↗
  5. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… First author DOI 10.1016/j.eclinm.2022.101764↗
  6. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(22)00066-3↗
  7. LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.21037/atm-22-907↗
  8. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(21)00286-2↗
  9. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. First author DOI 10.3389/fonc.2021.688576↗
  10. A novel lncRNA PTTG3P/miR-132/212-3p/FoxM1 feedback loop facilitates tumorigenesis and metastasis of pancreatic cancer. Co-author DOI 10.1038/s41420-020-00360-5↗
  11. Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.scib.2018.05.028↗
  12. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matc… Co-author DOI 10.2147/cmar.s163655↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yangsen Cao · 9 shared papers, 2018–2025 · strength 1.66
  2. Lingong Jiang · 8 shared papers, 2021–2025 · strength 1.59
  3. Xiaofei Zhu · 8 shared papers, 2018–2025 · strength 1.42
  4. Huojun Zhang · 8 shared papers, 2018–2025 · strength 1.38
  5. Yusheng Ye · 7 shared papers, 2021–2025 · strength 1.34
  6. Gang Jin · 3 shared papers, 2021–2022 · strength 0.48
  7. Xiaofei Zhu · 1 shared paper, 2025 · strength 0.25
  8. Shuiwang Qing · 2 shared papers, 2018–2021 · strength 0.19
  9. Chenming Ni · 1 shared paper, 2022 · strength 0.19
  10. Kailian Zheng · 1 shared paper, 2022 · strength 0.19
  11. Gang Li · 1 shared paper, 2022 · strength 0.19
  12. Ting‐Shi Su · 1 shared paper, 2021 · strength 0.12
  13. Xixu Zhu · 1 shared paper, 2021 · strength 0.12
  14. Xiangyu Kong · 1 shared paper, 2020 · strength 0.11
  15. Zhaoshen Li · 1 shared paper, 2020 · strength 0.11
  16. Huiqing Zhang · 1 shared paper, 2020 · strength 0.11
  17. Huiyun Zhu · 1 shared paper, 2020 · strength 0.11
  18. Fanyang Kong · 1 shared paper, 2020 · strength 0.11
  19. Kaixuan Wang · 1 shared paper, 2020 · strength 0.11
  20. Gang Y Jin · 1 shared paper, 2018 · strength 0.09
  21. Gang Yi · 1 shared paper, 2018 · strength 0.09
  22. Bin Li · 1 shared paper, 2018 · strength 0.09
  23. Shiwei Guo · 1 shared paper, 2018 · strength 0.09
  24. Yuxin Shen · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.